-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

747 Acalabrutinib and Rituximab in Elderly Patients with Newly Diagnosed Mantle Cell Lymphoma Including a Matched Population-Based External Comparator- the Nordic Lymphoma Group NLG-MCL8 (ALTAMIRA) Phase II Trial

Program: Oral and Poster Abstracts
Type: Oral
Session: 623. Mantle Cell, Follicular, Waldenstrom’s, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Updates on Drug Treatments for Mantle Cell Lymphoma, and CAR-T and Transplants for Indolent Lymphomas
Hematology Disease Topics & Pathways:
Research, Clinical trials, Lymphomas, Elderly, Clinical Research, B Cell lymphoma, Diseases, Treatment Considerations, Lymphoid Malignancies, Study Population, Human, Measurable Residual Disease
Monday, December 9, 2024: 11:00 AM

Mats Jerkeman, MD, PhD1, Karin Fahl Wader, MD, PhD2*, Ingrid Glimelius, MD, PhD3, Annika Pasanen, MD, PhD4*, Won Seog Kim5*, Louise Krüger Hansen6*, Jon Riise, MD, PhD7*, Martin Hutchings, MD, PhD8, Hashim Hussein Elhussein9*, Carsten Utoft Niemann, MD, PhD10*, Rasmus Rask Kragh Jørgensen, MSc11*, Tarec Christoffer El-Galaly, MD, DMSc, Prof12, Mats Ehinger, MD, PhD13*, Klaus Beiske, MD, PhD14*, Rose-Marie Amini15*, Michael Boe Møller16*, Marja-Liisa Karjalainen-Lindsberg, MD, PhD17* and Jacob Haaber Christensen, MD, PhD18*

1Division of Oncology, Skane University Hospital and Lund University, Lund, Sweden
2St Olav University Hospital, Department of Oncology, Trondheim, Norway
3Department of Immunology, Genetics and Pathology, Cancer Precision Medicine Unit, Uppsala University, Uppsala, Sweden., Uppsala University, Uppsala, Sweden
4Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland
5Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University, Seoul, Korea, Republic of (South)
6Aarhus University, Aarhus, Denmark
7Department of Oncology, Oslo University Hospital, Oslo, NOR
8Rigshospitalet and University of Copenhagen, Copenhagen, Denmark
9Rigshospitalet, Copenhagen, Denmark
10Department of Clinical Medicine, Dept. of Hematology, Rigshospitalet, Copenhagen, Denmark, Copenhagen, Denmark
11University of Aalborg, Aalborg, Denmark
12Department of Hematology, Aalborg Hospital, Aalborg, Denmark
13Lund University, Lund, SWE
14Oslo University Hospital, Oslo, Norway
15Department of Immunology, Genetics and Pathology, Uppsala University Hospital, Uppsala, Sweden
16Pathology, Odense University Hospital, Odense, Denmark
17Department of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
18Dept. of Hematology, Odense University Hospital, Odense, Denmark

Introduction: Although most patients with mantle cell lymphoma (MCL) are elderly, there is no universal established standard therapy for this population. Accumulating evidence show that BTK inhibitors may have an important role in front line regimens. Ibrutinib+ rituximab was recently compared to chemoimmunotherapy in the phase 3 ENRICH trial, but in vitro suggest that ibrutinib partially antagonizes the activity of rituximab through NK-cell inhibition. Acalabrutinib is not associated with NK-cell inhibition potentially and may thus be a more attractive combination partner with rituximab (AR). In this multicenter open-label phase II trial, we evaluated safety and efficacy of AR in elderly patients with MCL, including an MRD guided treatment duration strategy, as previously explored in the NLG-MCL7 (VALERIA) trial.

Methods: Main eligibility criteria were age ≥60 years, untreated MCL, non-eligible for transplant, WHO PS 0-3, and measurable disease by imaging. The primary endpoint was progression-free survival, and to provide a context for the single arm trial, an external comparator cohort was created using data were compared to a matched dataset from the population-based Swedish MCLcomplete project enrolling 1367 patients treated in the period 2006-2018. Matching was done by matching on sex and using nearest neighbor on MIPI score, in a 1:5 ratio for MCLcomplete. The most common regimens in the matched dataset were R-Bendamustine (33%) and NLG-MCL2 (18%). Minimal residual disease (MRD) monitoring by RQ-PCR was performed every 3 months during follow-up, according to EuroMRD criteria. Sequencing of the most frequently mutated genes in MCL was performed on formalin-fixed tumor tissue.

Treatment schedule: Acalabrutinib 100 mg BID in combination with rituximab 375 mg/m2 IV on day 1 every 28 days for 6 cycles, followed by treatment every 8 weeks. The minimum duration of treatment was 13 months. Patients in molecular remission in blood and bone marrow and in complete remission, would stop acalabrutinib, but continue with rituximab for up to 36 months. Patients with TP53 aberrations and/or blastoid histology continued with treatment until progression or unacceptable toxicity regardless of MRD results.

Results: In total, 81 patients were enrolled, from 18 sites in Sweden, Norway, Denmark, Finland and South Korea. The median age was 75 years, 61 (75%) were male and 56 (69%) were MIPI high risk. A TP53 mutation was detected in 19 (24%) of diagnostic biopsies, high Ki67 expression (>30%) in 18 (22%), and blastoid histology in 5 (6%). At 6 months, the ORR (n=61) was 95% (37 CR, 21 PR). The median follow-up is currently 15.5 months. PFS at 1 year is 86.5% (95% CI 78.9-94.8) , compared to 71.8% (95% CI 69.5-74.2) in MCLcomplete (p=0.016). OS at 1 year is 92.9% (95% CI 87.1-99.2) compared to 79.6% (95% CI 77.5-81.7) in MCLcomplete (p=0.012). Patients with TP53-mutated disease showed inferior outcome with a PFS of 69% at 1 year. At 12 months, 27 (59%) of 46 evaluable patients were MRD-negative, 14 were MRD+, 2 were not evaluable by MRD, and 3 are awaiting results. 19 out of 27 MRD-neg (70.4%) have stopped acalabrutinib at this point, and 5 continued treatment due to high risk biology. Another 2 patients stopped acala at 18 months, and one pt at 24 months, due to MRD-negativity. The most common grade 3-4 AE were neutropenia in 11 pts, infection in 10 pts, and cardiovascular toxicity in 7 pts. There have been 9 deaths, 3 due to MCL, 2 due to treatment-related toxicity (aplastic anemia and sepsis), and 4 due to other causes.

Conclusions: A response adapted treatment strategy, by stopping treatment in molecular remission appears to be feasible in MCL, even in an international multicenter trial setting. By comparison to matched population-based data, single arm clinical trial data may be set into a meaningful context, and frontline AR appear to be favorable compared to current standard therapy. Updated results will be presented at the meeting, including prolonged follow-up of MRD-negative patients after stopping acalabrutinib.

Disclosures: Jerkeman: Kite/Gilead: Honoraria; AstraZeneca: Honoraria, Research Funding; Abbvie: Honoraria, Research Funding; Janssen: Honoraria; Roche: Research Funding. Glimelius: AstraZeneca: Consultancy; Janssen: Speakers Bureau; Takeda: Honoraria, Other: Research Grant/Funding. Pasanen: Gilead, Roche, Incyte: Consultancy. Kim: Donga: Research Funding; Kyowa-Kirin: Research Funding; BeiGene: Research Funding; Sanofi: Research Funding; Boryong: Research Funding; Roche: Research Funding. Riise: AstraZeneca, Roche: Membership on an entity's Board of Directors or advisory committees. Hutchings: BMS/Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; AstraZeneca: Membership on an entity's Board of Directors or advisory committees, Research Funding; AbbVie: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Genmab: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Genentech: Research Funding; Incyte: Research Funding; Janssen/J&J: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Merck: Honoraria, Membership on an entity's Board of Directors or advisory committees; Novartis: Research Funding. Niemann: AbbVie, Janssen, AstraZeneca, Novo Nordisk Foundation, Octapharma: Consultancy, Research Funding; Novo Nordisk: Research Funding; CSL Behring, Genmab, Takeda, Beigene, MSD, Lilly: Consultancy.

OffLabel Disclosure: Acalabrutinib in previously untreated mantle cell lymphoma.

*signifies non-member of ASH